Hims & Hers Shares Sink 75.5%, Analysts See 150% Upside on $619M Revenue
Shares of Hims & Hers have dropped 75.50% from a May 2025 peak of $64.65 following a February lawsuit from Novo Nordisk alleging unlawful marketing of unapproved semaglutide versions. Analysts maintain a 12-month average price target of $39.32 and highlight record quarterly revenue of $619 million and an oversold RSI of 16.87.
1. Share Price Decline and Lawsuit
Hims & Hers equity has slumped 75.50% from its May 2025 high of $64.65 after Novo Nordisk sued the company in February 2026, alleging unlawful marketing of its own unapproved semaglutide formulations. The legal challenge has exacerbated investor concerns over Hims’ GLP-1 ambitions, driving the stock into oversold territory.
2. Analyst Targets and Upside Potential
Despite the downturn, 12-month analyst price targets average $39.32, implying nearly 150% upside. Bullish forecasts cite the stock’s RSI reading of 16.87 as an indicator of a potential near-term reversal and highlight the disparity between current market valuation and projected long-term growth.
3. Record Revenue and Diversified Growth Prospects
Hims & Hers reported record quarterly revenue of $619 million on February 23, driven by expanding telehealth services, hair-thinning treatments and sexual health supplements. Management emphasizes these diversified segments as growth engines beyond GLP-1-related headwinds, seeking to stabilize performance while resolving legal disputes.